Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics Inc (NQ: CYTH )

1.275 -0.005 (-0.36%)
Streaming Delayed Price Updated: 11:45 AM EDT, Jun 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cyclo Therapeutics Inc

< Previous 1 2 3 Next >
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Achievements
From Cyclo Therapeutics
Via Business Wire
Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Commences Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the China NPC Association Meeting
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Participate in the Virtual Investor Niemann-Pick Disease Type C Spotlight Event
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Participate in the Virtual Investor Alzheimer’s Disease Spotlight Event
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Enters Research and Collaboration Agreement with Wits Commercial Enterprise (Pty) Ltd to Explore Potential Applications of Trappsol® Cyclo™ to Expand Pipeline
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Provides Business Update and Reports Full Year 2021 Financial Results
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Selected to Present Overview of Pivotal Phase 3 Study for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2022
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference
From Cyclo Therapeutics, Inc.
Via Business Wire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /... 
From JTC Team, LLC
Via AccessWire
Cyclo Therapeutics Appoints Caroline Hastings, M.D. as Global Principal Investigator for Ongoing TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common Stock
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics Announces Proposed Public Offering of Common Stock
From Cyclo Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.